Patents by Inventor Gilles Pain
Gilles Pain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190167598Abstract: The invention relates to an improved tetrahydrobiopterin formulation for treating patients affected by hyperphenylalaninemia. More specifically, the formulation of the invention permits a prolonged residence of tetrahydrobiopterin in the plasma, and/or a higher concentration of sapropterin in the plasma, enabling notably the treatment of HPA patients that would usually not be classified as responders to tetrahydrobiopterin loading test, and therefore left without any pharmacological treatment opportunity, but only with a strictly controlled protein diet.Type: ApplicationFiled: July 27, 2017Publication date: June 6, 2019Inventors: Gilles PAIN, Fabio CANNATA, Bareket GELBHART
-
Patent number: 8669261Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.Type: GrantFiled: April 30, 2013Date of Patent: March 11, 2014Assignee: Congenia SLRInventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
-
Publication number: 20130245019Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.Type: ApplicationFiled: April 30, 2013Publication date: September 19, 2013Applicant: CONGENIA SRLInventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
-
Patent number: 8470831Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.Type: GrantFiled: September 23, 2009Date of Patent: June 25, 2013Assignee: Cogenia SRLInventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
-
Patent number: 8242175Abstract: New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, CH—NR3R4, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl, R11, R12 are, independently, hydrogen or C1-C6 alkyl, and R3, R4, R5 and R6 are as further defined in the specification.Type: GrantFiled: December 7, 2010Date of Patent: August 14, 2012Assignee: DAC S.R.L.Inventors: Antonello Mai, Saverio Minucci, Florian Thaler, Gilles Pain, Andrea Colombo, Stefania Gagliardi, Pier Giuseppe Pelicci, Marco Ballarini, Gaetano Gargiulo, Silvio Massa
-
Publication number: 20120115867Abstract: This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen or C1-C6 alkyl, R3, R4 are, independently, hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy, and R5 and R6 are as further defined in the specification, and pharmaceutical acceptable salts thereof.Type: ApplicationFiled: May 4, 2011Publication date: May 10, 2012Applicant: DAC S.R.L.Inventors: Saverio Minucci, Pier Giuseppe Pelicci, Antonello Mai, Marco Ballarini, Gaetano Gargiulo, Silvio Massa, Florian Thaler, Gilles Pain, Andrea Colombo, Stefania Gagliardi, Mario Varasi, Ciro Mercurio
-
Publication number: 20110195977Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.Type: ApplicationFiled: September 23, 2009Publication date: August 11, 2011Inventors: Daniele Fancelli, Varasi Mario, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
-
Publication number: 20110086893Abstract: Compounds formula (IA) or (IB), wherein W represents HO(C?O)—, HONH(C?O)— or H(C?O)N(OH)—; X represents —O— or —S—; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metal oproteinases, in particular MMP9 and/or MMP12.Type: ApplicationFiled: October 7, 2010Publication date: April 14, 2011Applicants: VERNALIS (OXFORD) LTD, LABORATOIRES SERONO S.A.Inventors: Andrew Paul AYSCOUGH, Stephen John DAVIES, Gilles PAIN, Jean-Yves GILLON
-
Publication number: 20110077247Abstract: New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, CH—NR3R4, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl, R11, R12 are, independently, hydrogen or C1-C6 alkyl, and R3, R4, R5 and R6 are as further defined in the specification.Type: ApplicationFiled: December 7, 2010Publication date: March 31, 2011Applicant: DAC S.r.I.Inventors: Antonello Mai, Saverio Minucci, Florian Thaler, Gilles Pain, Andrea Colombo, Stefania Gagliardi, Pier Giuseppe Pelicci, Marco Ballarini, Gaetano Gargiulo, Silvio Massa
-
Patent number: 7915304Abstract: The invention discloses the use of a compound of formula (I), wherein R1, R2, R3, and R4 each independently represents: hydrogen; halo; hydroxy; (C1-C6) alkyl optionally substituted by hydroxy or (C1-C4) alkoxy; (C1-C6) haloalkyl; (C1-C6) alkoxy; and (C1-C6) haloalkoxy; for the preparation of a medicament for the prevention and/or treatment of diseases resulting from opening of the MPTP which are characterized by degenerative tissue damages, in particular, diabetes and diabetic complications, neurological diseases and stroke, heart infarction, inherited dystrophies and hepatitis, more particularly, diabetic vascular diseases, such as diabetic retinopathy, and neurodegenerative disorders, such as multiple sclerosis. Further objects are a group of selected individual compounds of formula (I) for use as medicaments and a further group of selected individual compounds of formula (I) as novel compounds.Type: GrantFiled: September 21, 2007Date of Patent: March 29, 2011Assignee: Congenia S.r.l.Inventors: PierGiuseppe Pellicci, Marco Giorgio, Saverio Minucci, Paolo Bernardi, Gilles Pain, Stephen Martin Courtney, Christopher John Yarnold, Joachim Kraemer
-
Publication number: 20100280018Abstract: A compound of formula (I), or an enantiomer or diastereoisomer thereof, or a salt, hydrate or solvate thereof: for the treatment or prophylaxis of arthritis in mammals.Type: ApplicationFiled: July 20, 2010Publication date: November 4, 2010Applicants: Laboratoires Serono S.A., Vernalis (Oxford) LimitedInventors: Gilles Pain, Stephen John Davies, Agnes Bombrun
-
Patent number: 7786121Abstract: A compound of formula (I), or an enantiomer or diastereoisomer thereof, or a salt, hydrate or solvate thereof: for the treatment or prophylaxis of arthritis in mammals.Type: GrantFiled: August 18, 2004Date of Patent: August 31, 2010Assignees: Vernalis (Oxford) Limited, Laboratoires Serono S.A.Inventors: Gilles Pain, Stephen John Davies, Agnes Bombrun
-
Publication number: 20100113438Abstract: New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, CH—NR3R4, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl, R11, R12 are, independently, hydrogen or C1-C6 alkyl, and R3, R4, R5 and R6 are as further defined in the specification.Type: ApplicationFiled: March 30, 2007Publication date: May 6, 2010Applicant: DAC S.R.L.Inventors: Antonello Mai, Saverio Minucci, Florian Thaler, Gilles Pain, Andrea Colombo, Stefania Gagliardi
-
Publication number: 20100099736Abstract: The invention discloses the use of a compound of formula (I), wherein R1, R2, R3, and R4 each independently represents: hydrogen; halo; hydroxy; (C1-C6) alkyl optionally substituted by hydroxy or (C1-C4) alkoxy; (C1-C6) haloalkyl; (C1-C6) alkoxy; and (C1-C6) haloalkoxy; for the preparation of a medicament for the prevention and/or treatment of diseases resulting from opening of the MPTP which are characterized by degenerative tissue damages, in particular, diabetes and diabetic complications, neurological diseases and stroke, heart infarction, inherited dystrophies and hepatitis, more particularly, diabetic vascular diseases, such as diabetic retinopathy, and neurodegenerative disorders, such as multiple sclerosis. Further objects are a group of selected individual compounds of formula (I) for use as medicaments and a further group of selected individual compounds of formula (I) as novel compounds.Type: ApplicationFiled: September 21, 2007Publication date: April 22, 2010Applicant: Congenia S.R.L.Inventors: PierGiuseppe Pellicci, Marco Giorgio, Saverio Minucci, Paolo Bernardi, Gilles Pain, Stephen Martin Courtney, Christopher John Yarnold, Joachim Kraemer
-
Publication number: 20100035943Abstract: Compounds formula (IA) or (IB), wherein W represents HO(C?O)—, HONH(C?O)— or H(C?O)N(OH)—; X represents —O— or —S—; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metal oproteinases, in particular MMP9 and/or MMP12.Type: ApplicationFiled: October 14, 2009Publication date: February 11, 2010Applicants: VERNALIS (OXFORD) LTD, LABORATOIRES SERONO S.A.Inventors: Andrew Paul Ayscough, Stephen John Davies, Gilles Pain, Jean-Yves Gillon
-
Publication number: 20090069322Abstract: Compounds of formula (I) are antibacterial or antiprotozoal agents for treatment of infections in humans and non-human mammals, wherein: Z represents a radical of formula —N(OH)CH(?O) or formula C(?O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or except when Z is a radical of formula —N(OH)CH(?O), a hydroxy, halo or amino group; R2 represents a group R10—(X)n-(ALK)m— wherein R10, ALK, X, m and n are as defined in the specification; R3 represents hydrogen, (C1-C6) alkyl or phenyl(C1-C6)alkyl-; and R5 and R6 are as defined in the specification.Type: ApplicationFiled: September 26, 2006Publication date: March 12, 2009Applicant: British Biotech Pharmaceuticals Ltd.Inventors: Paul Raymond Beckett, Steven Launchbury, Gilles Pain, Lisa Marie Pratt
-
Publication number: 20080227833Abstract: Compounds formula (IA) or (IB), wherein W represents HO(C?O)—, HONH(C?O)— or H(C?O)N(OH)—; X represents —O— or —S—; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metal oproteinases, in particular MMP9 and/or MMP12.Type: ApplicationFiled: February 8, 2008Publication date: September 18, 2008Applicants: VERNALIS (OXFORD) LTD, LABORATOIRES SERONO S.A.Inventors: Andrew Paul AYSCOUGH, Stephen John Davies, Gilles Pain, Jean-Yves Gillon
-
Patent number: 7358265Abstract: Compounds formula (IA) or (IB), wherein W represents HO(C?O)—, HONH(C?O)— or H(C?O)N(OH)—; X represents —O— or —S—; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metalloproteinases, in particular MMP9 and/or MMP12.Type: GrantFiled: February 20, 2003Date of Patent: April 15, 2008Assignees: Vernalis (R&D) Ltd, Laboratories Serono S.A.Inventors: Andrew Paul Ayscough, Stephen John Davies, Gilles Pain, Jean-Yves Gillon
-
Patent number: 7173053Abstract: Compounds of formula (I) are antibacterial or antiprotozoal agents for treatment of infections in humans and non-human mammals, wherein: Z represents a radical of formula —N(OH)CH(?O) or formula C(?O)NH(OH); R1 represents hydrogen, methyl or trifluromethyl, or except when Z is a radical of formula —N(OH)(?O), a hydroxy, halo or amino group; R2 represents a group R10—(X)n-(ALK)m— wherein R10, ALK, X, m and n are as defined in the specification; R3 represents hydrogen, (C1–C6) alkyl or phenyl(C1–C6)alkyl-; and R5 and R6 are as defined in the specification.Type: GrantFiled: November 8, 2001Date of Patent: February 6, 2007Assignee: British Biotech Pharmaceuticals LimitedInventors: Paul Raymond Beckett, Steven Launchbury, Gilles Pain, Lisa Marie Pratt
-
Publication number: 20060281920Abstract: Compounds of formula (I) are inhibitors of matrix metalloproteinases, and are of use in the treatment of, for example fibrotic disease, multiple sclerosis, emphysemia, bronchitis and asthma: formula (I) wherein Ar represents an optionally substituted aryl, heteroaryl, C3-C8 cycloalkyl or heterocycloakyl group; R represents hydrogen or C1-C6 alkyl, or C3-C6 cycloalkyl; Alk represents a divalent C1-C5 alkylene or C2-C5 alkenylene radical; and R1 and R2 taken together with the nitrogen atom to which they are attached form a first heterocycloalkyl ring which is optionally fused to a second C3-C8 cycloalkyl or heterocycloalkyl ring, the said first and second rings being optionally substituted by at least one group of formula (II): formula (II) wherein m, p and n are independently 0 or 1; Z represents, hydrogen, or an optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms which is optionally fused to another optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atomsType: ApplicationFiled: August 18, 2004Publication date: December 14, 2006Applicants: Vernalis (Oxford) Limited, Laboratoires Serono S.A.Inventors: Gilles Pain, Stephen Davies, Agnes Bombrun